Devices and technology: Flash glucose monitoring

The results of the phase 2 LIBERATES trial suggest that flash glucose monitoring could reduce the time people with type 2 diabetes spend in hypoglycemia in the period following an acute coronary syndrome.

Analysis of flash glucose monitoring users in Scotland reveals that people with low socioeconomic status had an increased risk for deteriorating glycemic control during the COVID-19 lockdown.

UK audit data confirm multiple benefits linked to real-world use of flash glucose monitoring including reduced paramedic callouts and hospital admissions for acute diabetes complications.

Real-world data presented at the virtual ADA 80th Scientific Sessions highlight the benefits of the FreeStyle Libre continuous glucose monitoring system in reducing acute complications in people with type 1 or type 2 diabetes.

Italian researchers report that the slower pace of life forced on people with type 1 diabetes during lockdown amid the COVID-19 outbreak resulted in improved glycemic control.

Study results suggest that the accuracy of the FreeStyle Libre 14-day flash glucose monitoring system is adequate for patients with type 1 diabetes during its entire lifetime, although it tends to be less so during the beginning and end of its use.

Even minimal residual C-peptide secretion protects people with type 1 diabetes from hypoglycemic events, and reduces glycemic variability, show data from flash glucose monitoring.

People with type 1 diabetes remain broadly satisfied with flash glucose monitoring in the long term and its use may reduce acute diabetes complications and work absences, real-world data suggest.

Giving people with type 2 diabetes “wear-and-forget” masked flash glucose monitoring to allow their healthcare providers access to detailed glucose profiles is feasible in primary care, but it is not clear how beneficial this is, show the results of the GP-OSMOTIC trial.

Flash glucose monitoring significantly reduces time in hyperglycemia or hypoglycemia in people with diabetes at high risk for either outcome, with the benefit sustained for at least 6 months, real-world study data show.

Analyses of real-world audit data show positive initial results for the flash glucose monitoring system FreeStyle Libre and the sodium-glucose cotransporter 2 inhibitor canagliflozin.

Research shows that if people with diabetes recheck their glucose levels within 1 hour after receiving a low blood glucose alert from their flash glucose monitor it substantially reduces their risk for experiencing a long period of hypoglycemia.

Further findings from the pilot I-HART randomized trial suggest that switching from flash to continuous glucose monitoring reduces the time patients with type 1 diabetes spend in hypoglycemia

Flash glucose monitoring confers similar benefits for diabetes patients in the real world as for those using it in clinical trials, research shows.

Not all sites on the body are equal when it comes to the placement of the FreeStyle® Libre™ flash glucose monitor on patients with type 1 diabetes, say researchers.

A pilot randomized study suggests that continuous glucose monitoring may be better than flash monitoring for reducing hypoglycemia in type 1 diabetes patients with impaired awareness.

Children and adolescents with type 1 diabetes using a predictive low-glucose management system have less hypoglycemia and fewer hypoglycemic events than those managed using sensor-augmented pump therapy alone, according to a 6-month trial.

The flash glucose monitoring system FreeStyle Libre has received approval to be listed on the NHS Drug Tariff for the management of diabetes from 1st November 2017.

“Flash” glucose monitoring reduces the time adults with Type 1 diabetes spend in a hypoglycaemic state by about a third, research shows.